Reduces Postprandial Glucose Spikes: By slowing gastric emptying, GLP-1 ensures that nutrients are absorbed gradually rather than rapidly
Its triple GIP/GLP-1/glucagon agonist mechanism produced the most striking weight-loss numbers ever reported in a Phase 2 trial of an injectable peptide, and its broad TRIUMPH Phase 3 program is poised to expand understanding of how triple receptor modulation affects obesity, diabetes, liver disease, cardiovascular risk, sleep apnea, and musculoskeletal health
Amy shares why people have always wanted a magic pill for weight loss
In a small set of 8 people with GLPLS, it was found that taking tofacitinib twice a day led to improvements in the skin condition by 30-94%
If you need help broaching the subject, you can download a FREE toolkit, produced by the Obesity Action Coalition, at www.YourWeightMatters.org
Abstract GLP-1 receptor agonists represent a breakthrough for managing type-2 diabetes and obesity, offering metabolic benefits across multiple organ systems
